Q81.2 Insurance Policy Changes

ICD-10 Q81.2 is officially defined as "Epidermolysis bullosa dystrophica." code Q81.2 is referenced in 5 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Q81.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Effective Oct 3, 2025Medium impact
Prademagene Zamikeracel (Zevaskyn) (CPB 1084, reviewed 2026-05-27)
Aetna considers a one dose total of prademagene zamikeracel (Zevaskyn) medically necessary for treating wounds in members with recessive dystrophic epidermolysis bullosa (RDEB) when all of the listed criteria are met, including age 6 or older, biallelic COL7A1 pathogenic variants, positive NC1+ skin expression, and at least one stage 2 chronic wound open for 6 months or more. Members with an immune response to C7 by indirect immunofluorescence are ineligible, and the drug must be prescribed by or in consultation with a dermatologist or wound care specialist. Precertification of Zevaskyn is required of all Aetna participating providers and members in applicable plan designs.
Aetna · Identified Aug 16, 2026Medium impact
Skin and Soft Tissue Substitutes (CPB 0244, reviewed 2026-07-29)
Aetna's Clinical Policy Bulletin 0244 sets the coverage rules for skin and soft tissue substitutes used on chronic wounds. Aetna considers these products medically necessary for chronic wounds that failed to respond to treatment when the member is 18 or older, is a non-smoker or has completed or is enrolled in smoking cessation therapy, and the wound is a partial- or full-thickness skin defect of at least 1 cm2 that has not improved after at least four weeks of standard wound care. Diabetic foot ulcers, venous leg ulcers and partial- or full-thickness burn wounds have additional criteria, each listed product has its own indications, and pressure ulcer treatment and other uses are considered not medically necessary, experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Bone and Tendon Graft Substitutes and Adjuncts (CPB 0411, reviewed 2025-07-10)
Aetna considers INFUSE Bone Graft (bone morphogenetic protein-2) medically necessary for lumbar spinal fusion in skeletally mature persons who meet the lumbar spinal fusion criteria in CPB 0743 when it is implanted via an anterior (ALIF) or lateral (OLIF, DLIF, XLIF or LLIF) approach or with 1 or 2 level TLIF procedures, and for acute open tibial shaft fractures stabilized with intramedullary nail fixation when applied within 14 days after the initial fracture. Aetna considers INFUSE experimental, investigational, or unproven for ankle fusions, cervical fusions, 3 or more level TLIF procedures, and posterior or postero-lateral lumbar fusions. Cadaveric allograft and demineralized bone matrix are considered medically necessary for spinal fusions and for filling osteochondral defects, PMMA or calcium sulfate antibiotic beads are considered medically necessary with intravenous antibiotics for chronic osteomyelitis, and bone marrow injections are considered medically necessary for unicameral or simple bone cysts, while bone marrow aspirate and mesenchymal stem cell therapy are experimental for most orthopedic uses.
Aetna · Identified Aug 12, 2026Medium impact
Beremagene Geperpavec-svdt (Vyjuvek) (CPB 1033, reviewed 2026-06-12)
Aetna's clinical policy for Vyjuvek (beremagene geperpavec-svdt) applies to commercial medical plans, where Aetna's GCIT team gives it dedicated review, and precertification is required for all Aetna participating providers and members in applicable plan designs. Vyjuvek is medically necessary for treating open wounds in members with dystrophic epidermolysis bullosa (DEB) who have a confirmed pathogenic or likely pathogenic COL7A1 variant, when the target wounds meet the listed wound criteria and the member has not had a skin graft in the past three months. Aetna considers all other indications experimental, investigational, or unproven, and the maximum weekly dose is 2 x 10^9 PFU for patients under 3 years old and 4 x 10^9 PFU for patients 3 years and older.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
State and School Employees' Health Insurance Plan - Treatment of Epidermolysis Bullosa
Vyjuvek (beremagene geperpavec-svdt) may be considered medically necessary for dystrophic epidermolysis bullosa when the individual has a documented diagnosis, chart notes and laboratory values confirming a COL7A1 gene mutation, blistering wounds or scarring, and at least one recurrent or chronic open wound that meets the wound criteria. The policy criteria were revised to remove the age requirement, and that revision is dated 05/26/2026. Renewal requires prior approval through the BCBSMS review process, documented clinical improvement, and continued wound and prescriber criteria, with approval for 6 months.

Watch Q81.2

Get one email when a payer policy names Q81.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Q81.2?

There are 5 tracked policy changes affecting code Q81.2, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Q81.2?

Payers that have issued tracked updates for code Q81.2 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code Q81.2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Q81.2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Q81.2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Prademagene Zamikeracel (Zevaskyn) (CPB 1084, reviewed 2026-05-27)

Skin and Soft Tissue Substitutes (CPB 0244, reviewed 2026-07-29)

Bone and Tendon Graft Substitutes and Adjuncts (CPB 0411, reviewed 2025-07-10)

Beremagene Geperpavec-svdt (Vyjuvek) (CPB 1033, reviewed 2026-06-12)

State and School Employees' Health Insurance Plan - Treatment of Epidermolysis Bullosa

What insurance policy changes affect code Q81.2?

Which payers have updated policy for code Q81.2?

How do I get notified when code Q81.2 policy changes?

Why do payers change policies for code Q81.2?